non-small cell lung cancer

ESMO AstraZeneca
Biotech

AstraZeneca ends phase 3 cancer trial as bispecific underwhelms

AstraZeneca stopped the trial based on interim efficacy data, narrowing the opportunity for a bispecific designed to replace checkpoint inhibitors.
Nick Paul Taylor Aug 17, 2026 4:45am
Close up shot of the target from a dart game

Taiho and Cullinan secure lung cancer victory to challenge J&J

Aug 13, 2026 6:00am
sheet music wrong note

Arpeggio Bio disbands after Nrf2 program starts to ‘unravel’

Aug 10, 2026 5:04am
raised boxing glove with confetti falling around it

Roche orchestrates phase 3 lung cancer win over Amgen and BMS

Jul 2, 2026 8:30am
Person throwing piece of paper into full waste bin
Favicon Fierce Pharma

Nature retracts provocative PD-1 time-of-day study

Jun 24, 2026 11:00am
Pfizer

Pfizer’s first new ADC from Seagen buy fails ph. 3 NSCLC trial

Jun 23, 2026 7:15am